$18.52
+0.08 (+0.43%)
Open$18.62
Previous Close$18.44
Day High$18.71
Day Low$17.95
52W High$49.95
52W Low$6.50
Volume—
Avg Volume1.83M
Market Cap1.15B
P/E Ratio1.84
EPS$-43.00
SectorBiotechnology
Analyst Ratings
Strong Buy
13 analysts
Price Target
+87.6% upside
Current
$18.52
$18.52
Target
$34.74
$34.74
$25.90
$34.74 avg
$38.60
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 29.07M | 27.10M | 30.53M |
| Net Income | 5.84M | 4.59M | 6.02M |
| Profit Margin | 20.1% | 16.9% | 19.7% |
| EBITDA | 8.15M | 7.65M | 7.71M |
| Free Cash Flow | 6.21M | 7.09M | 6.33M |
| Rev Growth | +18.1% | +12.4% | +4.7% |
| Debt/Equity | 0.64 | 0.68 | 0.70 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $266.28 | +0.73% | 74.3 | 468.50B |
| AMGN | Amgen Inc | $418.13 | +0.85% | 25.1 | 219.78B |
| GILD | Gilead Sciences Inc | $152.21 | +0.85% | — | 185.02B |
| VRTX | Vertex Pharmaceuticals Inc | $527.67 | +0.28% | 30.5 | 134.17B |
| REGN | Regeneron Pharmaceuticals | $752.25 | -4.54% | 18.8 | 81.31B |
| ALNY | Alnylam Pharmaceuticals Inc | $255.36 | -0.23% | 41.4 | 33.44B |